Global Health Ventures Inc.
OTC Bulletin Board : GHLV

Global Health Ventures Inc.

March 22, 2010 09:25 ET

Global Health Ventures to Collaborate With PharmaLex of Mannhein Germany to File Clinical Dossier With European Regulatory Bodies

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 22, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) is pleased to announce that, the progress towards clinical trials is on schedule and going well. The Company has been required to file an Investigational Medicinal Product Dossier (IMPD) of the drug X-Excite with the European Regulatory bodies governing drug approval in the EU countries. This is an important documentation material for any new drugs which require regulatory approvals. Experienced companies can produce the documents in a manner which makes the product approval significantly faster. The Company has engaged PharmaLex GmbH of Germany to complete the dossier and file appropriately with the regulatory bodies.

"As our product approval is the most important element in the success of our business, we shall always engage and collaborate with the best companies that can guarantee our success", said Dr. Hassan Salari, President & CEO of Global Health.

About PharmaLex GmbH

PharmaLex GmbH is based in Mannheim, Germany and is one of most internationally well known Clinical Organization with extensive experience with the drug approval in Europe. PhamaLex has been helping biotechnology and pharmaceutical companies from around the world to obtain regulatory approval in Europe with high degree of success.

About Global Health Ventures

Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. X-Excite is presently in clinical trials in Europe.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products... Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Contact Information